Lilly gets FDA EUA for bebtelovimab in mild-to-moderate Covid-19
Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for bebtelovimab for the treatment of ... Read More
Lilly to launch real-world Covid-19 study of bamlanivimab in New Mexico
Eli Lilly and Company (Lilly), a global leader in the pharmaceutical industry, has announced plans to conduct a new pragmatic study of its experimental Covid-19 ... Read More
Lilly partners with UnitedHealth Group for pragmatic study of bamlanivimab in high-risk COVID-19 patients
Eli Lilly and Company (Lilly) has formed a strategic collaboration with UnitedHealth Group to conduct a pragmatic clinical study on bamlanivimab (LY-CoV555), a monoclonal antibody ... Read More
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA
The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly ... Read More
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt
Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, ... Read More